For two weeks, anyone with an opinion about BPC-157 and five other compounded peptides could tell the federal government what they thought. That window closed on Friday, November 13. The comment period on the Department of Health and Human Services’ interim enforcement-discretion policy, filed under docket HHS-OASH-2026-0496, is now shut. The department has not announced a withdrawal of the policy, but the question of what comes next remains open. HHS could retain the arrangement, revise it or reconsider its approach as formal rulemaking proceeds.
The dispute also leaves a less-discussed group of peptides in limbo: five substances that were removed from the FDA’s Category 2 list in April 2026 and are still awaiting further advisory review. Their removal from a list of substances raising significant safety concerns did not make them approved medicines or establish their eligibility for compounding.
For pharmacies, prescribers and patients, the difference between a regulatory permission, a promise of enforcement discretion and an FDA-approved drug is not academic. It determines what safeguards apply, who bears the regulatory risk and how much evidence exists to support the product being prescribed.
What the compounded peptides policy actually allows
HHS announced its approach on October 28, 2026. The notice was filed that day and officially published in the Federal Register on October 30. As Grey Pepper reported at the time, the policy covers six peptide substances: BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax.
The policy does not add any of them to the formal 503A Bulks List, which identifies certain ingredients that traditional compounding pharmacies may use under federal law. Instead, HHS describes circumstances in which it does not intend to take enforcement action against qualifying state-licensed pharmacies, federal facilities and licensed physicians that compound products using these substances.
A November 4 analysis from Holland & Knight explains that the policy is limited to particular chemical forms and routes of administration:
- BPC-157 acetate: Subcutaneous injection, intramuscular injection, oral and topical formulations.
- TB-500 acetate: Subcutaneous and intramuscular injectable formulations.
- Epitalon acetate: Subcutaneous and intramuscular injectable formulations, administered in intermittent courses.
- KPV acetate: Oral and topical formulations.
- MOTS-c acetate: Subcutaneous and intramuscular injectable formulations.
- Semax free base: Intranasal formulations only.
These distinctions are not optional. The specified peptide identity, including the applicable chemical structure, sequence and molecular properties, must match the policy’s requirements. Coverage of one form of a peptide does not automatically extend to every salt, derivative, combination or route of administration sold under a similar name.
The ten conditions for enforcement discretion extend beyond the identity of the peptide. In simplified terms, the policy requires:
- The peptide must appear on the policy’s 503A Interim Access List.
- Its identity, formulation and route of administration must match the specified requirements.
- The active pharmaceutical ingredient must come from an FDA-registered facility and have a valid certificate of analysis documenting appropriate characterization and testing.
- The original ingredient manufacturer must be FDA-registered, meet applicable manufacturing requirements and be identified by physical facility location on the certificate of analysis. Additional verification applies when intermediaries supply the ingredient.
- The compounder must report serious adverse events and relevant product-quality issues to FDA’s MedWatch program and applicable state authorities.
- The label must state: “This is a compounded drug product. Not for resale.”
- The compounded product must contain only one active pharmaceutical ingredient from the interim list.
- For oral formulations, the compounder must maintain documentation supporting adequate human oral bioavailability of the specific formulation.
- Any delivery device co-packaged with or containing the product must satisfy the policy’s restriction to an FDA 510(k)-cleared syringe.
- All other applicable federal and state requirements must be met, including sanitary conditions and Section 503A’s patient-specific prescription requirements.
Those requirements mean the policy is not a general authorization for peptide mixtures or retail products advertised under research-use-only labels. It also does not extend to all sellers, laboratories or pharmacies simply because a substance appears among the six names.
Enforcement discretion is a statement about when the government does not intend to act. It is not proof that a compounded peptide is safe or effective.
Why the 503A Bulks List still matters
The distinction between temporary discretion and formal listing is the central legal issue. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a bulk drug substance generally must meet one of several criteria: have an applicable United States Pharmacopeia or National Formulary monograph, be a component of an FDA-approved drug, or appear on the 503A Bulks List established by regulation. Other compounding requirements also apply.
HHS’s October policy does not change those statutory criteria. Holland & Knight notes that the enforcement-discretion framework creates no enforceable rights and has no binding legal effect. HHS can revisit the approach if safety signals, manufacturing problems or other concerns emerge. State licensing laws and pharmacy-board requirements also continue to apply.
A pharmacy developing products under this arrangement is therefore relying on a conditional federal enforcement position rather than a permanent authorization. The policy is intended to operate while the federal government considers whether the covered ingredients should eventually be placed on the 503A Bulks List through rulemaking.
The road to this point has been unusually contentious. In April 2026, the FDA announced the removal of twelve peptide substances from Category 2 of its interim 503A evaluation framework after the relevant nominators withdrew their nominations. The removals took effect on April 22.
FDA made clear that removing a substance from Category 2 did not make it eligible for compounding. The decision changed its status in the interim classification system, not its approval status or the legal requirements governing pharmacy compounding.
In July, the FDA’s Pharmacy Compounding Advisory Committee considered seven nominated peptide substances. It voted to recommend six for inclusion on the 503A Bulks List, but declined to recommend emideltide, also known as delta sleep-inducing peptide or DSIP. Those votes were advisory rather than legally binding.
The meeting also attracted scrutiny over the committee’s composition. According to Regulatory Affairs Professionals Society (RAPS), eight new members were appointed before the July meeting, and questions were raised about reported connections between some members and peptide prescribing or promotion. That controversy is part of the political context surrounding the subsequent HHS policy, although it does not by itself establish that the committee’s recommendations were invalid.
The five peptides still waiting
The April action left another group outside the October enforcement-discretion policy. As the healthcare law firm Frier Levitt explained in its review of the FDA’s updated interim lists, five substances were identified for further advisory committee consideration:
- Cathelicidin LL-37
- Dihexa acetate
- GHK-Cu for injectable routes of administration
- Pegylated mechano growth factor, or PEG-MGF
- Melanotan II
The FDA indicated that it intended to consult its Pharmacy Compounding Advisory Committee about those substances before the end of February 2027. That is a stated regulatory target, not confirmation that a meeting has been scheduled for a particular date.
Until further action, their position remains uncertain. They are no longer included in Category 2 on the basis of the withdrawn 503A nominations, but they have not gained access under the October HHS policy and have not been added to the formal 503A Bulks List.
GHK-Cu illustrates why route-specific language is important. FDA’s April changes addressed injectable GHK-Cu separately from non-injectable GHK-Cu, which had been the subject of a withdrawn Category 1 nomination. The regulatory history for the two routes should not be collapsed into a blanket statement about every product marketed as GHK-Cu.
The five substances also raise different scientific questions. LL-37 is an antimicrobial peptide investigated in preclinical research, while dihexa and PEG-MGF have attracted interest for speculative neurological or tissue-related applications. Melanotan II has been promoted for tanning, and injectable GHK-Cu has circulated in wellness and aesthetic markets.
None has FDA approval as a finished drug product for the promoted uses. More importantly, the scientific evidence cannot be treated as interchangeable across them. Human exposure data, safety findings and manufacturing concerns differ by substance and formulation. FDA has previously identified possible immunogenicity, peptide impurities, insufficient human safety information and, for certain substances, other serious potential risks.
Five peptides left Category 2 in April. None gained an automatic route onto the 503A Bulks List.
For pharmacies and patients, the question is not simply whether the compounds will be removed from a risk category or attract favorable votes. It is whether regulators will establish an appropriate legal pathway supported by sufficient evidence and safeguards for the intended formulations.
The critics and the government’s case
HHS has defended the October approach in part as a response to the market for research-use-only peptides obtained from foreign suppliers. Its argument is that a controlled pharmacy-compounding channel, subject to defined manufacturing, testing and reporting conditions, may offer patients an alternative to products sold through less accountable sources.
There is a distinction worth preserving here. A documented pharmaceutical ingredient supply chain, validated product identity and appropriate quality controls can reduce certain manufacturing and contamination risks. But improved manufacturing controls do not establish that a substance works for its promoted purpose or that its clinical risks are acceptable.
That is where the government’s position meets opposition from medical organizations and consumer advocates. Critics argue that moving toward wider clinical availability before adequate human safety and efficacy testing reverses the ordinary sequence of drug development.
Public Citizen’s Robert Steinbrook urged HHS to rescind the policy. Researchers and advocates associated with the Center for Science in the Public Interest also raised concerns about weakening established drug-evaluation safeguards, according to RAPS.
The American Medical Association took a formal position on November 9, 2026, adopting a policy urging HHS, the FDA and other federal authorities to rescind measures that ease restrictions on compounding and distributing unapproved synthetic peptides. As Grey Pepper reported in its earlier coverage, the AMA framed the issue as a patient-safety concern rather than simply a disagreement about pharmacy access.
In its public statements, the AMA emphasized missing clinical information, including validated pharmacokinetics, toxicology, dosing parameters and reliable evidence of effectiveness. Its concern is that clinicians cannot make well-supported treatment decisions merely because a peptide has an identifiable chemical composition and can be manufactured to specified quality standards.
For BPC-157, perhaps the most widely discussed of the six substances, published research remains heavily weighted toward laboratory and animal studies. Interest in recovery and tissue repair has moved much faster than robust controlled evidence demonstrating clinical benefit and safety in humans.
The dispute therefore involves two different kinds of risk. HHS emphasizes the dangers of an unregulated supply market and proposes a more controlled channel. Its critics emphasize the dangers of allowing clinical use without adequate evidence of safety and effectiveness. Those concerns can coexist, and neither is resolved by a certificate of analysis alone.

What to watch after the comments
The November 13 comment deadline does not automatically produce a final rule or an immediate decision on any peptide. HHS may consider the submissions and continue its announced enforcement position, modify its conditions or reconsider the policy. Any permanent addition to the 503A Bulks List would require a separate regulatory process.
The next important development is the expected advisory review of LL-37, dihexa acetate, injectable GHK-Cu, PEG-MGF and melanotan II. FDA identified a target of consultation before the end of February 2027, but readers should not mistake that target for a published meeting date or a commitment to approve any of the five substances.
The committee’s recommendations will matter, but they will not settle the issue on their own. The FDA must evaluate the relevant evidence and decide whether to pursue formal rulemaking. The tension between recommendations from advisory committee members and prior FDA scientific assessments will likely remain part of that process.
Another question is what happens as compounders begin operating under the policy’s reporting requirements. Reports of serious adverse events and product-quality problems could provide important safety signals. However, spontaneous reporting systems have limitations, including incomplete reporting and uncertainty about causation. Their existence should not be treated as a substitute for controlled clinical trials.
There is also a practical supply-chain bottleneck. Frier Levitt has noted that suitable pharmaceutical-grade active ingredients may not be readily available for every covered peptide. A compounder cannot satisfy the policy merely by purchasing a vial labeled with the correct name. The manufacturer’s registration, manufacturing controls, source verification, chemical identity and certificate of analysis must meet the applicable requirements.
State rules create another layer of uncertainty. A federal decision not to take enforcement action in specified circumstances does not prevent a state pharmacy or medical board from applying its own rules or investigating conduct it considers unlawful or unsafe.
The comment box is closed. The harder questions, about evidence, oversight and reliable supply, remain open.
For now, the federal government has drawn a narrow, conditional line around six peptide substances and left five more awaiting consideration. The public comment process has closed, but the evidence needed to justify durable regulatory decisions is still being debated.
What happens next will reveal whether the October policy becomes a bridge toward formal rules, is modified in response to scientific and legal criticism, or remains a temporary arrangement whose future depends on continued federal discretion.
Disclosure: Grey Pepper’s owner also has business interests in the research-peptide market.
Sources
- U.S. Department of Health and Human Services — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, October 30, 2026. Docket HHS-OASH-2026-0496.
- U.S. Department of Health and Human Services — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Policy text and Appendix A.
- Holland & Knight — HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides, November 4, 2026.
- Regulatory Affairs Professionals Society — HHS will permit compounding of six peptides ahead of formal rulemaking, October 29, 2026.
- Frier Levitt — FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List, April 16, 2026, with subsequent updates.
- U.S. Food and Drug Administration — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA reference information on nominated and withdrawn substances.
- American Medical Association — AMA adopts new policies to protect patients and strengthen public health, November 9, 2026.
- The American Journal of Managed Care — 5 Things to Know About HHS’s Interim Peptide Compounding Policy, October 29, 2026.
- Grey Pepper — Six Peptides, Ten Conditions: Washington Opens a Narrow Compounding Door, October 30, 2026.
- Grey Pepper — Doctors’ Biggest Lobby Wants HHS to Undo Its Peptide Compounding Pause, November 12, 2026.

